AZGP1P2 and neoplasm: Furthermore, in vivo assay with the subcutaneous xenograft mouse model showed that AZGP1P2 overexpression decreased the tumor growth of CRPC cells treated with docetaxel (Fig. 2O and P and Fig. S2), which illustrates that AZGP1P2 plays an important role in improving the sensitivity of docetaxel chemotherapy in CRPC cells.